Physician profile
Debra Ann Carson
NPI 1043410392
$806.92
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $142 · 2021: $140 · 2022: $273.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $474.61 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.91 | 2019 | |
| Medtronic, INC. | $43.31 | 2022 | |
| Mayne Pharma Commercial LLC | $41.85 | 2022 | |
| Daiichi Sankyo INC. | $37.49 | 2020-2021 | |
| Novo Nordisk INC | $37.40 | 2022 | |
| Sage Therapeutics, LLC | $20.72 | 2022 | |
| Merck Sharp & Dohme LLC | $17.82 | 2021 | |
| Organon LLC | $16.34 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.56 | 2022 | |
| Exeltis, USA INC. | $14.90 | 2022 | |
| Myovant Sciences INC. | $14.76 | 2022 | |
| Smith+Nephew, INC. | $13.81 | 2022 | |
| Agile Therapeutics, INC. | $13.44 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.